CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
E2014 (Botulinum toxin type B) +1 moredrug
Likely dose
E2014 (Botulinum toxin type B) 20 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00280384
NCT00280384Phase 2Completed

An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects

Eisai Limited·interventional·Posted Jan 23, 2006·Updated Apr 25, 2013

In Brief

A Phase 2 clinical trial evaluating E2014 (Botulinum toxin type B) and E2014 (Botulinum toxin type B) Placebo for Spasmodic Torticollis. Completed, enrolled 48 participants across 1 site.

Detailed Summary

To evaluate inter-ethnic similarity in pharmacodynamics between Japanese and Caucasian healthy adult male subjects by comparing electrophysiological reactions after administering E2014 to extensor digitorum brevis muscle (EDB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2006
Enrollment StartJan 1, 2006
Primary CompletionAug 1, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 20.4 years ago

Interventions

E2014 (Botulinum toxin type B)drug

A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.

E2014 (Botulinum toxin type B) Placebodrug

A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.